A Non-interventional, Observational Cohort Study of Chronic Lymphocytic Leukaemia Patients Treated With Acalabrutinib in the First-line Setting Through the UK Early Access Programme: Early Access Programme Outcomes In aCalabrutinib (EPIC).
Status: Recruiting
Location: See all (29) locations...
Intervention Type: Drug
Study Type: Observational
SUMMARY
This is a retrospective observational research study to describe the characteristics and real-world clinical outcomes of patients with chronic lymphocytic leukaemia receiving acalabrutinib in the United Kingdom (the EPIC study). Physicians treating chronic lymphocytic leukaemia patients with acalabrutinib, where the patients started treatment as part of the acalabrutinib Early Access Programme (EAP), will be invited to recruit patients. Clinical data will be extracted from the patients' clinical records in line with local laws. Data from this study will provide UK-specific real-world data on patients who were started on acalabrutinib as part of the UK acalabrutinib EAP.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 130
Healthy Volunteers: f
View:
• Treatment-naïve CLL patients who were initiated on acalabrutinib as part of the UK Early Access Programme
• Received their first dose of acalabrutinib between 1 April 2020 and 1 April 2021
• Patients aged ≥18 years old
⁃ Note: patients later found to have small lymphocytic lymphoma (SLL) may also be included in the EAP.
Locations
Other Locations
United Kingdom
Research Site
RECRUITING
Aylesbury
Research Site
RECRUITING
Bath
Research Site
RECRUITING
Birmingham
Research Site
RECRUITING
Bournemouth
Research Site
RECRUITING
Cardiff
Research Site
RECRUITING
Cornwall
Research Site
RECRUITING
Dartford
Research Site
RECRUITING
Derby
Research Site
RECRUITING
Doncaster
Research Site
RECRUITING
Dorset
Research Site
RECRUITING
Eastbourne
Research Site
RECRUITING
Hull
Research Site
RECRUITING
Leicester
Research Site
RECRUITING
Lincoln
Research Site
RECRUITING
Liverpool
Research Site
RECRUITING
London
Research Site
RECRUITING
London
Research Site
RECRUITING
Mid Yorkshire
Research Site
RECRUITING
Middlesbrough
Research Site
RECRUITING
Newcastle
Research Site
RECRUITING
North Shields
Research Site
RECRUITING
Norwich
Research Site
RECRUITING
Nottingham
Research Site
RECRUITING
Oxford
Research Site
RECRUITING
Plymouth
Research Site
RECRUITING
Southampton
Research Site
RECRUITING
Stockton-on-tees
Research Site
RECRUITING
Stoke-on-trent
Research Site
RECRUITING
Wigan
Contact Information
Primary
AstraZeneca Clinical Study Information Center
information.center@astrazeneca.com
1-877-240-9479
Time Frame
Start Date:2022-10-17
Estimated Completion Date:2027-04-01
Participants
Target number of participants:350
Treatments
Group 1
Patients with chronic lymphocytic leukaemia treated with acalabrutinib in first line